Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus

Virol Sin. 2022 Feb;37(1):145-148. doi: 10.1016/j.virs.2022.01.014. Epub 2022 Jan 18.

¹ School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
² National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
³ National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: [email protected].
⁴ School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: [email protected].

Abstract

•
Tilorone dihydrochloride possesses robust anti-SFTSV activity in vitro and in vivo.
•
Intraperitoneal administration of tilorone leads to protection against intracranial lethal challenge of SFTSV.
•
The anti-SFTSV mechanism of tilorone is through stimulation of host innate immunity.
•
Pre-treatment with tilorone can prevent mice from lethal SFTSV challenge.